Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer

Clinical Cancer Research

Volumn 20, Issue 11, 2014, Pages 3012-3022

  Escudier, Bernard ^a   Grünwald, Viktor ^c   Ravaud, Alain ^b   Ou, Yen Chuan ^e   Castellano, Daniel ^g   Lin, Chia Chi ^f   Gschwend, Jürgen E ^d   Harzstark, Andrea ^h   Beall, Sarah ^c   Pirotta, Nicoletta ^c   Squires, Matthew ^c   Shi, Michael ^c   Angevin, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AXITINIB; BEVACIZUMAB; CALCIUM; DOVITINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR 23; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACENTAL GROWTH FACTOR; SODIUM; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRIACYLGLYCEROL; TROPONIN T; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; QUINOLONE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; ECG ABNORMALITY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEMIPARESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY METASTASIS; LUNG EMBOLISM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NONCARDIAC CHEST PAIN; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; SKIN DISEASE; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STOMATITIS; T WAVE; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; SALVAGE THERAPY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINOLONES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SALVAGE THERAPY;

EID: 84901804554     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3006     Document Type: Article

References (40)

1. Rasmussen N, Rathmell WK. Looking beyond inhibition of VEGF/ mTOR: emerging targets for renal cell carcinoma drug development. Curr Clin Pharmacol 2011;6:199-206.
2. Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012;33:9-16.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-90. (Pubitemid 41770167)
4. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992-1000.
5. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-71.
6. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
7. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747-57. (Pubitemid 36613033)
8. Auguste P, Javerzat S, Bikfalvi A. Regulation of vascular development by fibroblast growth factors. Cell Tissue Res 2003;314:157-66. (Pubitemid 37409921)
9. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78. (Pubitemid 40616114)
10. Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013;84:115-22.
11. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9:639-51.
12. Welti JC, Gourlaouen M, Powles T, Kudahetti SC, Wilson P, Berney DM, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011;30:1183-93.
13. Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005;11:5281-91. (Pubitemid 41003717)
14. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41. (Pubitemid 40685578)
15. Angevin E, Lopez-Martin J, Lin CC, Gschwend JE, Harzstark A, Castellano D, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013;19:1257-68.
16. Dent S, Zee B, Dancey J, Hanauske A, Wanders J, Eisenhauer E. Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 2001;19:785-91. (Pubitemid 32119094)
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
18. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258) - an inhibitor of fibroblast growth factor receptors and VEGF receptors-in patients with advanced melanoma. Clin Cancer Res 2011;17:7461.
19. Tamaskar I, Dhillon J, Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2011;9:101-10.
20. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104:93-113.
21. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
22. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with IFN-a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
23. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
24. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
25. Sarker D,Molife R, Evans TR, Hardie M,Marriott C,Butzberger-Zimmerli P, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patientswith advanced solid tumors. ClinCancerRes 2008;14:2075-81. (Pubitemid 351551118)
26. Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011;16:432-44.
27. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
28. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7:475-85. (Pubitemid 46809172)
29. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon-α compared with interferon-α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8.
30. Escudier B, Eisen T, StadlerWM,Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
31. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-α in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
32. Grunwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinomawith VEGF-targeted therapies. Br J Cancer 2011;105:1635-9.
33. Iacovelli R, Carteni G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013;49:2134-42.
34. Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010; 58:906-11.
35. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 2010;116:5400-6.
36. Harrison MR, George DJ, Walker MS, Chen C, Korytowsky B, Kirkendall DT, et al. "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy. Clin Genitourin Cancer 2013;11:441-50.
37. Miyake H, Kusuda Y, Harada K, Sakai I, Fujisawa M. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol 2013; 18:81-6.
38. Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer 2013;11:45-50.
39. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8.
40. Motzer RJ, Szczylik C, Vogelzang N, Sternberg CN, Porta C, Zolnierek J, et al. Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy. Eur Cancer Congr 2013 (ECCO-ESMOESTRO) 2013:Abstract 34LBA.